Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database

摘要: Metaplastic breast cancer (MBC) is characterized by chemoresistance and hematogenous spread. We sought to identify factors associated with improved MBC outcomes increased likelihood of diagnosis. Women ≥ 18 years age stage I–III non-MBC diagnosed between 2010 2014 were identified in the National Cancer Data Base. Kaplan–Meier multivariate Cox proportional hazards models used estimate associations overall survival (OS). Multivariate logistic regression Overall, 2451 568,057 patients included; 70.3% vs. 11.3% triple negative (p < 0.001). Five-year OS was reduced among for entire cohort (72.7 87.5%) triple-negative (71.1 77.8%; both p < 0.001). In MBC, (vs. luminal) subtype not worse (hazard ratio [HR] 1.16, 95% confidence interval [CI] 0.88–1.54, p = 0.28). Compared patients, more likely receive mastectomy (59.0 44.9%), chemotherapy (74.1 43.1%), axillary lymph node dissection (ALND; 35.2 32.2%, all p ≤ 0.001). frequently had ALND (pN0) than (20.0 10.6%, Among (HR 0.69, CI 0.53–0.89, p = 0.004) radiotherapy 0.52, 0.39–0.69, p < 0.001) survival, while decreased 1.37, 1.06–1.77, p = 0.02). independent receptor status, suggesting that may confer an additional disadvantage. Multimodal therapy outcomes, but be overutilized MBC.